Видео ютуба по тегу Flt3-Itd

The prognostic value of FLT3-ITD residual disease in AML
The prognostic value of FLT3-ITD residual disease in AML
FLT3 Mutations’ Impact on Prognosis and Treatment in AML
FLT3 Mutations’ Impact on Prognosis and Treatment in AML
Ингибиторы FLT3-тирозинкиназы в лечении острых миелоидных лейкозов. Антипова А. С.
Ингибиторы FLT3-тирозинкиназы в лечении острых миелоидных лейкозов. Антипова А. С.
The impact of FLT3-inhibitor maintenance post alloSCT in AML with FLT3-ITD and NPM1/DNMT3A mutations
The impact of FLT3-inhibitor maintenance post alloSCT in AML with FLT3-ITD and NPM1/DNMT3A mutations
Dr. Levis on the Challenges of Treating FLT3-ITD AML
Dr. Levis on the Challenges of Treating FLT3-ITD AML
Best treatment strategy for FLT3 ITD AML
Best treatment strategy for FLT3 ITD AML
Prognostic impact of FLT3-ITD in older patients with AML
Prognostic impact of FLT3-ITD in older patients with AML
Сравнение транскриптомов пациентов с диагнозом ОМЛ при наличии и отсутствии мутации FLT3-itd
Сравнение транскриптомов пациентов с диагнозом ОМЛ при наличии и отсутствии мутации FLT3-itd
The impact of conditioning intensity on MRD in patients with FLT3-ITD AML undergoing alloSCT
The impact of conditioning intensity on MRD in patients with FLT3-ITD AML undergoing alloSCT
Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial
Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial
What is FLT3-positive AML? What is gilteritinib? #AML
What is FLT3-positive AML? What is gilteritinib? #AML
Dr. Röllig on FLT3 ITD/NPM1 Mutation Status for Patients With AML
Dr. Röllig on FLT3 ITD/NPM1 Mutation Status for Patients With AML
Management & outcome of patients with CBF AML and FLT3-ITD
Management & outcome of patients with CBF AML and FLT3-ITD
Should Clinicians Use FLT3 Inhibitor Maintenance in FLT3-ITD AML? MRD Helps Inform the Decision
Should Clinicians Use FLT3 Inhibitor Maintenance in FLT3-ITD AML? MRD Helps Inform the Decision
Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML
Comparing midostaurin to next-generation FLT3 inhibitors in the frontline treatment of FLT3-ITD AML
The prognostic impact of FLT3-ITD and FLT3-TKD in NPM1-mutated AML
The prognostic impact of FLT3-ITD and FLT3-TKD in NPM1-mutated AML
FLT3-TKI synergises with BCL-2 inhibitor to eliminate FLT3/ITD AML cells through BIM activation
FLT3-TKI synergises with BCL-2 inhibitor to eliminate FLT3/ITD AML cells through BIM activation
Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in AML
Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in AML
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quiza...
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quiza...
QuANTUM-First: FLT3-ITD-specific MRD clearance is associated with improved OS in newly diagnosed AML
QuANTUM-First: FLT3-ITD-specific MRD clearance is associated with improved OS in newly diagnosed AML
Понимание FLT3 при ОМЛ: что это означает и как это лечится
Понимание FLT3 при ОМЛ: что это означает и как это лечится